Vercauteren M P, Coppejans H C, Hoffmann V H, Mertens E, Adriaensen H A
Department of Anesthesiology, University Hospital Antwerp, Edegem, Belgium.
Anesth Analg. 2000 Feb;90(2):324-7. doi: 10.1097/00000539-200002000-00016.
To evaluate the effectiveness of prophylactic ephedrine for the prevention of hypotension associated with spinal anesthesia, 50 parturients undergoing cesarean delivery received either ephedrine 5 mg or saline IV in a double-blinded fashion immediately after the induction of spinal anesthesia. Spinal anesthesia was performed with hyperbaric bupivacaine 6.6 mg combined with sufentanil 3.3 microg as part of a combined spinal-epidural technique. All patients received 1000 mL of lactated Ringer's solution and 500 mL of hydroxyethylstarch 6% before the spinal injection. Additional ephedrine boluses (5 mg) were administered IV when the systolic blood pressure or heart rate decreased by more than 30% from baseline values, when systolic blood pressure became <100 mm Hg, or when patients complained of nausea or feeling faint. The height of the block was equal in the groups; however, more patients in the placebo group were found to develop hypotension (58% vs 25%, P < 0. 05). Only 2 (8%) patients in the ephedrine group developed hypotension with systolic blood pressure values <90 mm Hg, whereas 10 patients (42%) in the saline group experienced hypotension of this severity (P < 0.05). In addition, there was a higher incidence of nausea in the placebo-treated patients. The total amount of ephedrine administered did not differ between groups. These findings suggest that the incidence and severity of hypotension are significantly reduced by the IV administration of a prophylactic dose of 5 mg ephedrine in patients receiving small-dose spinal anesthesia for cesarean delivery.
Ephedrine is the drug most often used to correct hypotension during spinal anesthesia for cesarean delivery in healthy patients. A single IV dose of 5 mg decreases the occurrence and limits the severity of hypotension in prehydrated subjects receiving a small-dose spinal local anesthetic-opioid combination.
为评估预防性使用麻黄碱预防脊髓麻醉相关低血压的效果,50例行剖宫产的产妇在脊髓麻醉诱导后立即以双盲方式静脉注射5 mg麻黄碱或生理盐水。采用重比重布比卡因6.6 mg联合舒芬太尼3.3μg进行脊髓麻醉,作为腰麻 - 硬膜外联合麻醉技术的一部分。所有患者在脊髓注射前均输注1000 mL乳酸林格氏液和500 mL 6%羟乙基淀粉。当收缩压或心率较基线值下降超过30%、收缩压降至<100 mmHg或患者主诉恶心或头晕时,静脉追加麻黄碱推注(5 mg)。两组的阻滞平面相同;然而,安慰剂组有更多患者发生低血压(58%对25%,P<0.05)。麻黄碱组仅有2例(8%)患者发生收缩压<90 mmHg的低血压,而生理盐水组有10例(42%)患者出现如此严重程度的低血压(P<0.05)。此外,安慰剂治疗患者恶心发生率更高。两组间麻黄碱的总用量无差异。这些结果表明,对于接受小剂量脊髓麻醉剖宫产的患者,静脉注射5 mg预防性剂量的麻黄碱可显著降低低血压的发生率和严重程度。
麻黄碱是健康患者剖宫产脊髓麻醉期间最常用于纠正低血压的药物。单次静脉注射5 mg可降低接受小剂量脊髓局部麻醉 - 阿片类药物联合麻醉且已充分补液患者低血压的发生并减轻其严重程度。